Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

Share Price is delayed by 15 minutes
Get Live Data
849.50    -28.50 (-3.25%)
Bid:
852.50
Ask:
854.50
Spread: 2.00 (0.235%)
Market Cap: £978.40m
KNOS Live PriceLast checked at - London Stock Exchange

Intraday Kainos Group Share Chart

Trading Update

16 Apr 2020 07:00

RNS Number : 8041J
Kainos Group plc
16 April 2020
Β 

16 April 2020

Β 

Kainos Group plc

("Kainos" or "the Company")

Trading Update

Β 

Kainos Group plc, a leading provider of Digital Services and Platforms, today issues a trading update for the year ended 31 March 2020.Β 

Β 

Trading in the period continued with positive momentum and the Company expects results for the full year ending 31 March 2020 to be in line with current market consensus forecasts.

Β 

A clear focus on execution throughout the year has resulted in an excellent sales performance and a substantial backlog as the company enters FY21. The Company continued to generate cash from operations and has a robust balance sheet with no debt and a cash balance in excess of Β£40m.Β 

Β 

Kainos expects to announce results for the year ended 31Β March 2020 on Tuesday 26 May 2020, in line with prior years' timetable.

Β 

COVID-19

Β 

Throughout the Coronavirus pandemic our priorities have been ensuring the wellbeing of our people and supporting our customers in these difficult times.

Β 

We invoked our response plan on 5 March, implementing home working for over 1,700 staff in a seamless fashion and without disruption to our customer projects. We are grateful for the active agreement of our customers in placing our people in the safest possible environment to provide on-going support for all our customer engagements.

Β 

Several of our customers are at the forefront of responding to Coronavirus and we are supporting their efforts: from COVID-19 amendments to the NHS App; supporting consular services for UK citizens living or stranded overseas; and to emergency passport applications for urgent and compassionate reasons.

Β 

In the current environment, digital access to essential services has become extremely important. We have therefore taken steps to offer, pro bono, the expertise of some of our most experienced colleagues to help key government departments, care providers and organisations provide digital services to those that need them most. Our people have engaged on these projects with enthusiasm, and we hope they have supported the phenomenal efforts of those serving on the health and social care frontlines.

Β 

Cost Containment

Β 

We anticipate that our customers in government and healthcare will likely be more robust than those in other sectors during this crisis. Nevertheless, we feel it is important to be prudent and manage the cost base, without limiting our longer-term growth prospects.

Β 

Therefore, Kainos is currently implementing several cost and cash containment measures, which include placing staff on furlough, pausing recruitment and reducing all non-essential expenditure, including deferment of the capital investment relating to the proposed new office in Belfast. These will result in significant cost savings on the prior year cost run-rate.

Β 

Given the backdrop, several measures have been taken in relation to remuneration to ensure further cost containment. Across the Group, pay increases have been deferred until 2021 and bonus schemes have been curtailed. Additionally, for a period of six months, effective 1 April 2020, the Executive Directors (CEO, CFO and SVP Business Development) have elected to take no salary or bonus, the remaining members of the executive team have reduced their compensation by 50% and the Non-Executive Board members have reduced their fees by 20%.

Β 

Cash

Β 

As at 31 March 2020, Kainos had cash deposits in excess of Β£40m and no debt.

Β 

Notwithstanding the security of this strong cash balance and the cost reduction measures already implemented, in order to preserve the Group's liquidity during this period, the Board considers it prudent to maintain flexibility on dividends at this stage.

Β 

Accordingly, the Board has decided it shall not declare a final dividend for FY20 but will take the opportunity to review this decision later in the year as the impact of COVID-19 becomes clearer.

Β 

Outlook

Β 

Kainos provides digital technology services and platforms critical to over 550 high-quality customers across the globe. Revenues from its end markets are increasingly diversified and mainly recurring or repeating in nature.

Β 

Whilst this provides confidence, and despite there being only limited impact to date, the Board believe that is too early to predict the duration or the severity of the economic disruption and any impact it will have on our customers.

Β 

The Board maintains confidence in its strategy, and believes that the Group has acted quickly and prudently to the uncertainty of the current situation, which will leave it well positioned when the economic impacts of the Coronavirus begin to recede.

Β 

- ENDS-

Β 

Β 

For further information, please contact:

Β 

Kainos

via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

Β 

Investec Bank plc

Patrick Robb / Ben Griffiths

+44Β 20 7597 5970

Canaccord Genuity

+44 20 7523 4606

Simon Bridges / Andrew Potts

Β 

FTI Consulting LLP

+44 20 3727 1000

Matt Dixon / Dwight Burden

Β 

Β 

About Kainos

Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms.

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading boutique partner for Workday, Inc. ('Workday') in Europe, responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise customers.

The Group's Digital Platforms comprise specialised digital products in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records (EMR) is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.

Kainos has over 1,700 people across 12 offices in Europe and the USA.

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTIAMPTMTTBBIM
Date   Source Headline
4th Jun 202611:31 amRNSDirector / PDMR shareholdings
1st Jun 202610:27 amRNSTotal Voting Rights
18th May 20267:00 amRNSFull Year Results
18th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 202611:06 amRNSTotal Voting Rights
28th Apr 20261:38 pmRNSBoard and Board Committee Changes
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSYear-end Trading Update
14th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 202610:22 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20265:10 pmRNSDirector Declaration
24th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20263:16 pmRNSNotification of Major Holdings
17th Mar 202611:28 amRNSDirector/PDMR shareholdings
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20264:58 pmRNSNotification of Transactions of Director/PDMR
12th Mar 20262:13 pmRNSHolding(s) in Company
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20269:30 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20269:43 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.